Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 717-722

  Shen, Yonghua ^a   Chen, Min ^a   Huang, Shuling ^a   Zou, Xiaoping ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Apoptosis; Gastric cancer; Proton pump inhibitors; Pyruvate kinase M2; Tumor metabolism

Indexed keywords

PANTOPRAZOLE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN EXPRESSION; SGC 7901 CELL; STOMACH ADENOCARCINOMA; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84948844425     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3912     Document Type: Article

References (31)

1. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
2. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Béroud C, Demont J, Bouvier R, Schägger H and Godinot C: Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23: 759-768, 2002.
3. Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q and Wang Q: Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med 30: 302-308, 2012.
4. Furtado CM, Marcondes MC, Sola-Penna M, de Souza ML and Zancan P: Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS One 7: e30462, 2012.
5. Kosugi M, Ahmad R, Alam M, Uchida Y and Kufe D: MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One 6: e28234, 2011.
6. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T and Stoddard BL: The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 6: 195-210, 1998.
7. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
8. Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186, 2008.
9. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480: 118-122, 2011.
10. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, et al: Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283, 2011.
11. Goldberg MS and Sharp PA: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 209: 217-224, 2012.
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
13. Wang LY, Liu YP, Chen LG, Chen YL, Tan L, Liu JJ, Jazag A, Ren JL and Guleng B: Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells. PLoS One 8: e67542, 2013.
14. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH and Cho JY: Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 18: 4037-4043, 2012.
15. Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS, Yoo HS, Kim WH, Xie Z, Pocalyko D, et al: Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 423: 38-44, 2012.
16. Blume H, Donath F, Warnke A and Schug BS: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29: 769-784, 2006.
17. Shen Y, Wu Y, Chen M, Shen W, Huang S, Zhang L and Zou X: Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells. Neoplasma 59: 142-149, 2012.
18. Tao T, Li G, Dong Q, Liu D, Liu C, Han D, Huang Y, Chen S, Xu B and Chen M: Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells. Tumour Biol 35: 8543-8550, 2014.
19. Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, Kim HC and Hahm KB: Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 10: 8687-8696, 2004.
20. Czernin J and Phelps ME: Positron emission tomography scanning: Current and future applications. Annu Rev Med 53: 89-112, 2002.
21. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2: 683-693, 2002.
22. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, Wang XH, Mu B, Wang W, Ma Y et al: Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 101: 1447-1453, 2010.
23. Cortés-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P, Sellers WR and Hofmann F: M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 110: 489-494, 2013.
24. Chen M, Huang SL, Zhang XQ, Zhang B, Zhu H, Yang VW and Zou XP: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.
25. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S and Zwerschke W: Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res 315: 2765-2774, 2009.
26. Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 137: 65-72, 2011.
27. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Dürr P, Eigenbrodt E and Zwerschke W: Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 123: 312-321, 2008.
28. Hamanaka RB and Chandel NS: Targeting glucose metabolism for cancer therapy. J Exp Med 209: 211-215, 2012.
29. Tamada M, Suematsu M and Saya H: Pyruvate kinase M2: Multiple faces for conferring benefits on cancer cells. Clin Cancer Res 18: 5554-5561, 2012.
30. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R et al: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108: 4129-4134, 2011.
31. Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK et al: A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 385: 16-21, 2009.